TROP2: as a promising target in lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Lung cancer (LC) remains a major global health challenge, necessitating innovative treatment strategies.
• Trophoblast cell surface antigen-2 (TROP2) is highly expressed in various tumors, including lung cancer, but minimally in normal tissues.
• This differential expression makes TROP2 an attractive target for selective cancer therapies.

Purpose of the Study:

• To review the characteristics of TROP2 and its involvement in cancer progression.
• To highlight advancements in TROP2-targeted antibody-drug conjugates (ADCs) for cancer treatment.
• To assess the therapeutic potential of TROP2-ADCs in managing lung cancer.

Main Methods:

• Literature review of TROP2 biology and its role in oncogenesis.
• Analysis of TROP2 expression patterns in normal and tumor tissues.
• Evaluation of TROP2-targeted antibody-drug conjugate (ADC) development and clinical data.

Main Results:

• TROP2 is overexpressed in tumor tissues, particularly lung cancer, and its expression correlates with disease progression.
• TROP2-targeted ADCs have demonstrated efficacy in preclinical and clinical studies.
• One TROP2-ADC has received FDA approval, validating its therapeutic potential.

Conclusions:

• TROP2 is a validated therapeutic target for lung cancer.
• TROP2-ADCs represent a significant advancement in LC treatment.
• Further research and clinical application of TROP2-ADCs hold promise for improving patient outcomes in lung cancer.